CN1144669A - Medicine for treatment of burn - Google Patents
Medicine for treatment of burn Download PDFInfo
- Publication number
- CN1144669A CN1144669A CN 95110539 CN95110539A CN1144669A CN 1144669 A CN1144669 A CN 1144669A CN 95110539 CN95110539 CN 95110539 CN 95110539 A CN95110539 A CN 95110539A CN 1144669 A CN1144669 A CN 1144669A
- Authority
- CN
- China
- Prior art keywords
- burn
- medicine
- group
- skt
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A medicine for curing burn and scald is prepared from 8 Chinese medicinal materials such as scutellaria root, giant knotweed rhizome, forsythia fruit, rhubarb, capejasmine fruit, etc., and features good action to stop pain of wound, eliminate edema, improve microcirculation of burn and scald, inhibit bacterial growing, and good water and air permeability.
Description
The present invention relates to field of pharmaceutical technology, is a kind of medicine for the treatment of burn and scalding.
The medicine of burn is more, but curative effect is still not good enough.Particularly to present treatment burn surface area more greatly, darker patient, present existing medicine can not reach quickly alleviating pain, eliminate edema, improve the burn microcirculation and have the effect of stronger bacteriostasis.
The objective of the invention is, a kind of Chinese medicine preparation for the treatment of burn is provided, make it have good wound surface pain relieving, eliminate edema, improve the burn microcirculation and have stronger bacteriostasis, permeable, permeability is good, drain is unobstructed, can alleviate secondary injury, promote wound healing, reduces the advantage of cicatrization.
The component and the amount ranges of medicine of the present invention are: Radix Scutellariae 6-10g, Rhizoma Polygoni Cuspidati 6-10g, Fructus Forsythiae 4-8g, Radix Et Rhizoma Rhei 3-6g, Fructus Gardeniae 3-6g, Borneolum Syntheticum 1-3g, Cera Flava 6-9g, 100 milliliters in Oleum Sesami.The component of medicine of the present invention and consumption are Radix Scutellariae 8g, Rhizoma Polygoni Cuspidati 8g, Fructus Forsythiae 6g, Radix Et Rhizoma Rhei 5g, Fructus Gardeniae 5g, Borneolum Syntheticum 2g, Cera Flava 7g, 100 milliliters in Oleum Sesami.
Preparation method of the present invention: with component of the present invention,, on electric furnace, be heated to (140-160 ℃) then by consumption requirement dedusting, remove impurity, Oleum Sesami soaked overnight, continue about 20 minutes (looking the medicine change color decides) and filter, remove the gred.Cera Flava heating purification (160-180 ℃) is filtered in the oily extract.Treating that temperature is reduced to about 60 ℃ adds Borneolum Syntheticum, last quantitatively packing, seal, labeling, packing.
The pharmacodynamics test of medicine of the present invention:
1, analgesic test: adopt mice hot plate method and mouse writhing method, experimental result shows that SKT has tangible analgesic effect, compares with blank group and JINGWANHONG group, and highly significant meaning (P＞0.01) is all arranged.
2, antiinflammatory test: select for use Ovum Gallus domesticus album to cause rat paw edema and the scorching two kinds of methods of mouse ear caused by dimethylbenzene xylene.Experimental result shows that SKT has the good inhibition rat paw edema and the effect of mice ear, with the blank group highly significant meaning (P＜0.01) is arranged relatively, and significantly is better than JINGWANHONG.
3, erythrocyte osmotic fragility test: adopt variable concentrations sodium chloride method, experimental result shows that the SKT prescription element has the effect of stable erythrocyte membrane, and inferring has the effect of stablizing other cell membrane equally, and this is significant to improving the burn microcirculation.
4, the stripped ileum of mice shrinks inhibition test: the stripped ileum of normal mouse can be wriggled in normal saline naturally.Experimental result shows that SKT prescription composition has the effect of obvious inhibition intestinal tube smooth muscle movement, the intestinal tube number of times of wriggling is naturally obviously reduced, and suppress to strengthen with the drug level increase, compare significance (P＜0.05) and highly significant meaning (P＜0.01) with the blank group, show that also its inhibition is not is permanent, but reversible, this oozes out significant to improving burn microcirculation and minimizing.
5, extracorporeal bacteria inhibitor test: adopt the flat board method that burrows, result of the test shows: SKT all has good bacteriostasis to staphylococcus aureus, bacillus pyocyaneus, escherichia coli, Bacillus proteus, its inhibition zone diameter is respectively 13.50+1.77,15.62+1.60,10.60+1.32,8.80+1.10mm, and the control drug JINGWANHONG does not then have antibacterial ring.
6, charrin's disease mice endogenous protective test adopts mouse back to scald, with 10
9/ ml bacillus pyocyaneus causes into infection model.Divide SKT, JINGWANHONG and saline control group, divide different time to get crust undertissue then and carry out count of bacteria, experimental result shows, saline control group and JINGWANHONG matched group amount of bacteria all increase day by day, the SKT group is then on a declining curve, SKT group and the relatively more existing remarkable meaning (P＜0.05) of two matched groups during to the 3rd day, this difference more obvious (P＜0.01) during to the 6th and the tenth day shows that wound can scribble the ability that good anti Bacillus pyocyaneu Flugge infects.
7, wound healing test: select healthy guinea pig for use, make dark II degree scalding model with test tube scald method, carry out the coating treatment with SKT and JINGWANHONG respectively then, divide different time to survey the healing rate and the cicatrization rate of wound surface diameter, calculating healing speed and different time, result of the test shows: SKT and JINGWANHONG two medicine groups and blank group are relatively, its healing speed and healing rate all have highly significant meaning (P＜0.01), and two medicine group difference nonsignificances (P＞0.05).Cicatrization rate SKT group obviously reduces, than JINGWANHONG group low 9%.
The toxicology test of medicine of the present invention:
1, skin acute toxicity test: selecting rabbit for use is experimental animal, divide intact skin group and damaged skin group, experimental result shows: two groups of rabbit there is no any untoward reaction, and the medication part is not show, swollen phenomenon also, shows that SKT is to the not toxigenicity reaction of rabbit short term contact.
2, skin long term toxicity test: laboratory animal is a rabbit, divide saline control group and SKT group, continuous use 45 days, the 24 hours blood of coring is done blood test, biochemical investigation and is carried out system and becomes celestial after the last administration, core simultaneously, liver,spleen,kidney and skin (agents area) send pathology to carry out histological examination, experimental result shows: two treated animal hematological examinations and biochemical investigation result be all in normal range, system's no abnormality seen that becomes celestial.The histological examination no abnormality seen.The delayed toxicity reaction is not seen in restorative observation, shows that SKT is nontoxic, harmless to rabbit.
3, skin irritation test: laboratory animal is a Cavia porcellus, divides the blank group, complete sum damaged skin group, and experimental result demonstration SKT is normal and damaged skin nonirritant to Cavia porcellus.
4, skin allergy experiment: laboratory animal is a Cavia porcellus.Divide the blank group, positive control (2,4-dinitro-chloro-benzene) group and experimental group.Experimental result shows that positive controls erythema and edema are all very obvious, and blank and experimental group be skin smooth then, no erythema, no edema, does not show any anaphylaxis.
5, PCEMNR micronucleus test: divide negative matched group (saline).Positive controls (CP) and experimental group, experimental result show that the negative control group micronuclear rates is 2.33+1.03 ‰, and the CP group is that 2.67+1.21 ‰ shows that SKT does not have potential mutagenesis to mice for 22.16+2.92 ‰, experimental group.
6, mouse marrow cell chromosome aberration test: divide negative matched group (saline): positive controls (CP) and experimental group, experimental result shows.The negative control group aberration rate is 1.5%, and the CP group is 23.0%, and experimental group is 1.0%, shows that SKT does not cause the increase of mouse marrow cell chromosome aberration rate.
Medicine of the present invention is through clinical practice 144 examples, burn 122 examples wherein, cure rate is 97.5%, average healing natural law: shallow II degree is 5-11 days, and dark II degree is 13-25 days, relatively has remarkable meaning (P＜0.01) with the Oleum Radix Arnebiae (Oleum Radix Lithospermi) matched group, shallow II degree shifts to an earlier date healing in 2-3 days, dark II healing in long 4-5 days is in advance surplused 22 examples for ulcer and patients with bedsore, all receives excellent curative.
Medicine of the present invention proves to have good wound surface pain relieving, eliminate edema, improve the microcirculatory advantage of burn through clinical and animal experiment.And have a stronger bacteriostasis, permeable, permeability is good, drain is unobstructed, can alleviate secondary injury, promote the face wound healing, reduce cicatrization, use convenient, do not emphasize strict gnotobasis.
Claims (2)
1, a kind of medicine for the treatment of burn, it is characterized in that: its component and amount ranges are: Radix Scutellariae 6-10g, Rhizoma Polygoni Cuspidati 6-10g, Fructus Forsythiae 4-8g, Radix Et Rhizoma Rhei 3-6g, Fructus Gardeniae 3-6g, Borneolum Syntheticum 1-3g, Cera Flava 6-9g, 100 milliliters in Oleum Sesami.
2, according to the described a kind of medicine for the treatment of burn of claim 1, it is characterized in that: its component and consumption are Radix Scutellariae 8g, Rhizoma Polygoni Cuspidati 8g, Fructus Forsythiae 6g, Radix Et Rhizoma Rhei 5g, Fructus Gardeniae 5g, Borneolum Syntheticum 2g, Cera Flava 7g, 100 milliliters in Oleum Sesami.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 95110539 CN1144669A (en) | 1995-07-13 | 1995-07-13 | Medicine for treatment of burn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 95110539 CN1144669A (en) | 1995-07-13 | 1995-07-13 | Medicine for treatment of burn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1144669A true CN1144669A (en) | 1997-03-12 |
Family
ID=5077912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 95110539 Pending CN1144669A (en) | 1995-07-13 | 1995-07-13 | Medicine for treatment of burn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1144669A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446290A (en) * | 2013-07-12 | 2013-12-18 | 六枝特区人民医院 | Burn tincture as well as preparation method and application thereof |
| CN110051738A (en) * | 2019-04-30 | 2019-07-26 | 叶柳兴 | It is a kind of specially to control burn and scald specific prescription |
-
1995
- 1995-07-13 CN CN 95110539 patent/CN1144669A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446290A (en) * | 2013-07-12 | 2013-12-18 | 六枝特区人民医院 | Burn tincture as well as preparation method and application thereof |
| CN103446290B (en) * | 2013-07-12 | 2015-04-22 | 六枝特区人民医院 | Burn tincture as well as preparation method and application thereof |
| CN110051738A (en) * | 2019-04-30 | 2019-07-26 | 叶柳兴 | It is a kind of specially to control burn and scald specific prescription |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109078165B (en) | Composition for nursing female private parts and preparation method and application thereof | |
| CN104857312B (en) | A kind of Chinese medicine composition of preventing and treating wound infection promotion wound healing | |
| CN102058781A (en) | Traditional Chinese medicinal film agent for treating burns and scalds | |
| CN100333763C (en) | Preparation method of bed sore flesh engendering ointment | |
| CN1879791A (en) | A nasal drop for treating rhinitis and method for preparing same | |
| CN103055052A (en) | Cream for treating burn and scald and preparation method of cream | |
| CN114159511B (en) | Traditional Chinese medicine preparation for preventing and treating radioactive skin injury and preparation method thereof | |
| CN1052420C (en) | Chinese medicine for curing burn and traumatic wound and its production method | |
| CN105147773B (en) | Traditional Chinese medicine composition with acne inhibition effect and preparation method and application thereof | |
| CN1144669A (en) | Medicine for treatment of burn | |
| CN101062085B (en) | Condyloma acuminata treating medicine | |
| CN102370710A (en) | Medicament for treating otitis media and preparation method thereof | |
| CN1927292A (en) | External use drug for treating burn, bedsore, chronic ulcer and etc. and preparation method thereof | |
| CN1927362A (en) | Traditional Chinese powder medicine for treating toothache | |
| CN113577172A (en) | Traditional Chinese medicine external cream for treating diabetic foot and preparation method and application thereof | |
| CN1148214C (en) | Medicine for curing bronchial asthma disease and its preparing method | |
| CN1169863A (en) | Chinese medicine preparation for sore, ulcer and infection caused by external wound and preparation method | |
| CN1087948C (en) | Fast-acting burn and scald treating liquid | |
| CN105055622B (en) | A kind of Chinese medicine film-forming gel agent treating either shallow bed sore at ulcerative stage | |
| CN104857089B (en) | A kind of decoction for treating rheumatism and rheumatoid arthritis and preparation method thereof | |
| CN1167430C (en) | Broad-spectrum antibacterial Huangru Ointment for treating deep burn | |
| CN1076613C (en) | Skin-cleaning sterilizing agent (Ziguang oil) | |
| CN107714781B (en) | Pharmaceutical composition for treating burns and scalds and preparation method and application thereof | |
| CN114272290B (en) | A topical compound Chinese medicinal extract for treating cancer pain of all steps, and its preparation method | |
| CN1297292C (en) | Burn treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |